<DOC>
	<DOCNO>NCT02618577</DOCNO>
	<brief_summary>NOAH investigator-initiated , prospective , parallel-group , double-blind , randomised , multi-centre trial . The objective trial demonstrate oral anticoagulation use NOAC edoxaban superior current therapy pre-vent stroke , systemic embolism , cardiovascular death patient AHRE least two stroke risk factor without AF . The trial conduct several European country .</brief_summary>
	<brief_title>Non-vitamin K Antagonist Oral Anticoagulants Patients With Atrial High Rate Episodes</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) common cause stroke , especially ischemic stroke . So far , available data demonstrate beneficial effect oral anticoagulation stroke prevention collect population AF document conventional ECG recording . It well establish large proportion AF episodes remain undiagnosed ( `` silent AF '' ) , many patient present stroke first clinical sign AF . Earlier initiation anticoagulation could prevent event . Continuous monitor atrial rhythm implant device could close diagnostic gap . Pacemakers , defibrillator , cardiac resynchronisation device already provide automate algorithm alert occurrence highly organised atrial tachyarrhythmia episode , also call `` subclinical atrial fibrillation '' , commonly , `` atrial high rate episode '' ( AHRE ) . Data large prospectively follow patient cohort demonstrate stroke rate increase patient AHRE . A sizeable portion patient develop clinically detect AF time . In patient , AHRE consider early manifestation paroxysmal AF . A AHRE patient develop clinically overt AF , absolute stroke rate low patient AHRE compare stroke rate patient clinically diagnose AF . In light bleed complication associate oral anticoagulant therapy , thus uncertainty optimal antithrombotic therapy patient AHREs . The Non-vitamin K antagonist Oral anticoagulant ( NOACs ) provide similar slightly good stroke prevention , appear slightly safe compare vitamin K antagonist ( VKAs ) . In addition , individual therapy adjustment NOACs perform . Edoxaban , newly introduce NOAC , dose regime 60 mg daily ( OD ) favourable profile compare dose-adjusted VKA therapy : In ENGAGE-TIMI 48 trial , edoxaban prevent stroke least effectively VKA therapy cause less major bleed event VKA therapy .</detailed_description>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>1 . Implanted pacemaker defibrillator feature detection AHRE , implant least 2 month prior randomisation . 2 . AHRE detection feature activate adequately accord `` Suggestions optimal programming device adequate detection AHRE '' ( refer Appendix VIII ) . 3 . AHRE ( ≥ 180 bpm atrial rate ≥ 6 min duration ) document implanted device via atrial lead store digitally . AHRE episode detect first 2 month implantation new device involve placement reposition electrode count . AHRE episodes record first two month simple `` box change '' operation , i.e . exchange pacemaker defibrillator device without exchange reposition electrode , eligible . 4 . Age ≥ 65 year . 5 . In addition , least one follow cardiovascular condition lead CHA2DS2VASc score 2 : Age ≥ 75 year ; Heart failure ( clinically overt LVEF &lt; 45 % ) ; Arterial hypertension ( chronic treatment hypertension , estimate need continuous antihypertensive therapy rest blood pressure &gt; 145/90 mmHg ) ; Diabetes mellitus ; Prior stroke transient ischemic attack ( TIA ) ; Vascular disease ( peripheral , carotid/cerebral , aortic plaque transesophageal echocardiogram [ TEE ] ) . 6 . Provision sign informed consent . General exclusion criterion E1 . Any disease limit life expectancy le 1 year . E2 . Participation another control clinical trial , either within past two month still ongoing . E3 . Previous participation present trial NOAH . E4 . Drug abuse clinically manifest alcohol abuse . Exclusion criterion related cardiac condition E5 . Any history overt AF atrial flutter . E6 . Indication oral anticoagulation ( e.g . deep venous thrombosis ) . E7 . Contraindication oral anticoagulation general . E8 . Contraindication edoxaban state current SmPC . E9 . Indication longterm antiplatelet therapy acetylsalicylic acid , especially dual antiplatelet therapy ( DAPT ) acetylsalicylic acid one follow agent : clopidogrel , prasugrel , ticagrelor . Patients transient requirement DAPT ( e.g . receive stent ) eligible need DAPT longer present . E10 . Acute coronary syndrome , coronary revascularisation ( PCI bypass surgery ) , overt stroke within 30 day prior randomisation . Exclusion criterion base laboratory abnormality E11 . End stage renal disease ( creatinine clearance ( CrCl ) &lt; 15 ml/min calculate CockcroftGault method ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>atrial high rate episode</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>VKA</keyword>
	<keyword>NOAC</keyword>
</DOC>